Labora Rounds: The Innovation & Funding Brief

🌟 ESSENTIAL BRIEF

This Week’s Signal

Federal research funding for women’s health faces existential threat while private innovation races ahead with FDA approvals—creating a two-tier system where those who can pay access cutting-edge care while safety-net patients lose even basic research protections.

Federal Moves

NIH awarded $4.5 million BIRCWH grants to Emory, Mount Sinai, and Boston University for women’s health research training, while facing proposed budget cuts and reorganization from 27 institutes to 5 that would eliminate the National Institute on Minority Health and Health Disparities entirely. October’s government shutdown forced NIH to operate at 24% staff for two weeks, freezing grant reviews. The Women’s Health Initiative narrowly survived April cancellation after public outcry. Gates Foundation pledged $2.5 billion through 2030 ($280 million annually) for contraceptive development and maternal health innovation.

For Your Practice

Three FDA-approved innovations entering practice now: Mirvie Encompass (blood test predicting preeclampsia with 91% accuracy), Teal Wand (first at-home cervical cancer screening), and Miudella (hormone-free IUD). Major VC funding: Midi Health raised $50 million for virtual menopause care, Seven Starling secured $8 million for maternal mental health. Yet only 0.6% of 2025 VC funding reached all-female founding teams—even in women’s health innovation, gender inequity persists. When patients ask about these products, understand clinical evidence, equity implications, and insurance coverage gaps.

State Divergence

Expanding access: California allocated $50 million for reproductive health innovation incubators; Washington created regulatory fast-tracks for femtech.

Restricting access: Texas and Florida created compliance barriers making telehealth contraception economically unviable for startups.

Innovation geography: 73% of venture-backed femtech companies headquartered in five states (CA, NY, MA, TX, IL), creating regional access disparities.

This Week’s Actions

Do now:

Review preeclampsia screening protocols and prepare patient education about predictive diagnostics. Research whether Mirvie Encompass is available in your region and what it costs patients.

Plan for:

December webinar on evaluating femtech claims versus wellness marketing; develop framework for assessing new technologies pre-adoption.

Watch:

NIH reorganization comment period opens November 30—proposed elimination of dedicated women’s health research offices including Office of Research on Women’s Health. Submit comments using practice examples.

💡 OPENING

For birthworkers, this week crystallizes a fundamental tension: breakthrough technologies reach the market at record speed while the public research infrastructure that made them possible is being systematically dismantled.

TIME magazine celebrates three women’s health innovations—a preeclampsia predictor, at-home cervical cancer test, hormone-free IUD—each addressing genuine access gaps.

Yet these emerge against federal research chaos: NIH grants frozen mid-study, proposed budget cuts that would eliminate entire institutes dedicated to minority health and women’s health research.

The Innovation Paradox: Despite femtech growing 160% faster than the broader healthcare market, only 0.6% of 2025 venture capital went to all-female founding teams.

The private sector fills the gap on its own terms: serving those who can pay, focusing on profitable conditions, bypassing safety-net systems where your most vulnerable patients receive care.

Your commercially insured patients ask about Mirvie’s preeclampsia test; your Medicaid patients won’t access it for years. You’re excited about hormone-free contraception, but companies target consumers affording $500+ out of pocket.

This week requires navigating not just clinical questions about new technologies, but equity questions about who benefits and who gets left behind.

📊 WHAT’S HAPPENING IN WASHINGTON

Federal Research Under Assault

NIH faces unprecedented assault: proposed reorganization collapsing 27 institutes into 5 mega-institutes, eliminating the National Institute on Minority Health and Health Disparities entirely ($534 million annually)—explicitly targeting DEI-focused research. The proposed budget would also dismantle dedicated women’s health research offices that have driven innovation for decades.

Despite this, NIH continues awarding critical grants. Three institutions received $4.5 million each through BIRCWH (Building Interdisciplinary Research Careers in Women’s Health):

Emory University: Five-year renewal for women’s health research training

Mount Sinai: First K12 grant for women’s life-course exposomics

Boston University: Focus on addiction, maternal health, sex differences

These fund junior faculty studying reproductive outcomes and health disparities—exactly what the administration’s budget would eliminate.

October Shutdown Impact: NIH operated with only 24% staff for two weeks. New grants and peer review panels froze, creating a backlog that continues to delay critical women’s health research.

Current impacts: Grant funding frozen mid-study, forcing researcher layoffs. National Cancer Institute cannot plan long-term trials. Junior scientists abandon academic research.

Women’s Health Initiative: Near-Death Experience

April’s announced cancellation of most WHI studies—tracking 161,000 women since 1991—was reversed only after massive public pressure. The study costs $10 million annually (0.03% of NIH budget).

WHI’s Impact: Research credited with preventing 126,000 breast cancer cases and 76,000 heart disease cases. When politically motivated cuts can target a $10 million study with proven public health impact, no research is safe.

Global Health Collaboration Severed

September’s “America First” strategy permanently rescinded $0.9 billion for HIV/AIDS, family planning, and reproductive health programs.

Why Global Innovation Matters: Many maternal health innovations originate in global health research.

AI-enabled ultrasound, mobile screening technologies, and improved maternal risk assessment tools are often piloted in Kenya, Ethiopia, or South Africa before reaching rural and safety-net U.S. settings.

When federal policy severs these partnerships, philanthropy can temporarily fill the gap, but the long-term pipeline of shared learning and infrastructure is put at risk.

Private Funding Responds

Gates Foundation’s $2.5 billion commitment through 2030 ($280 million annually)—its largest women’s health investment ever—supports maternal health, contraceptive development, and infectious disease prevention, catalyzing research in understudied areas like preeclampsia, non-hormonal contraceptives, and the vaginal microbiome.

One example this week: a Gates challenge grant to Haramaya University in Ethiopia to build a life-course Women’s Health Index in low-resource settings, piloting AI-powered portable ultrasound to identify high-risk pregnancies earlier.

⏰ IMPLEMENTATION TIMELINE

January 2026: Deadline for NOSI on U3 Populations research (NOT-OD-24-179) - focuses on health of underrepresented, underserved, and underreported populations

November 30, 2025: NIH reorganization comment period opens - proposed elimination of Office of Research on Women’s Health and dedicated women’s health institutes

Through 2030: Gates Foundation $2.5B ($280M annually) for women’s health innovation, focusing on contraceptive technologies and maternal health

🔬 WHAT’S COMING TO YOUR PRACTICE

Immediate (2025-2026): Technologies Entering Practice

Mirvie Encompass: Predictive Preeclampsia Testing

Analyzes gene expression in maternal blood predicting preeclampsia risk (91% accuracy, 10,000-patient study). Identifies high-risk patients early enough for low-dose aspirin, increased monitoring, planned delivery.

Clinical utility: Stratifies risk more precisely than clinical criteria for patients with preeclampsia risk factors.

Equity concern: Costs $400-600 out-of-pocket, not covered by most insurance.

The Access Gap: Black women have 60% higher preeclampsia risk and are disproportionately on Medicaid—the tool that could most benefit them is least accessible.

Teal Wand: At-Home Cervical Cancer Screening

First FDA-approved at-home screening addresses major barrier—many women avoid Pap smears due to discomfort or trauma. Self-collection at home with comparable sensitivity to clinician-collected samples.

Clinical utility: New option for patients years overdue for screening.

Implementation gap: Need protocols for ordering, tracking, follow-up. When self-collected samples return HPV-positive, how do you transition patients to colposcopy when they’ve specifically avoided clinic visits?

Coverage: Inconsistent—some plans cover as preventive care, others consider investigational.

Miudella: Hormone-Free IUD

First truly hormone-free IUD in decades (Paragard uses copper). Novel mechanism not relying on hormones or metals. Expands options for patients with contraindications to hormones or copper IUD problems.

Evidence base: Newly approved; long-term data still collecting. Be transparent about 5-10 year outcome uncertainty.

Egal Pads on a Roll: Dignified Menstrual Access

Menstrual pads designed for easy dispensing in public facilities—addressing affordability and accessibility barriers that keep menstruators from school, work, and public life.

Equity impact: Unlike high-tech innovations requiring insurance or smartphone apps, this addresses fundamental access. Available in public restrooms like toilet paper.

Why Basic Matters: Period poverty affects 1 in 4 U.S. teens. Basic menstrual products shouldn’t require navigating healthcare systems or affording $10+ retail packages. Sometimes the most important innovation is making the essential accessible.

Venture Capital Surge: Where Money’s Going

Midi Health: $50 million Series C (total $150M raised) for virtual menopause care, serving ~20,000 patients weekly. Building AI-powered women’s health search engine addressing misinformation in medical search tools.

Training Gap: Only ~30% of OB/GYN residencies offer menopause training; women spend 9+ years in menopausal transition.

Seven Starling: $8 million for maternal mental health platform, expanding nationwide to tackle disparities where traditional healthcare fails.

Hims & Hers: Launched dedicated menopause telehealth (Oct 15), serving 500,000+ subscribers, projecting $1B+ revenue in 2026.

Partnership ecosystem: Transcarent integrated Maven Clinic (fertility/pregnancy), Midi Health (menopause), and Progyny (fertility benefits), creating a unified digital entry point that helps women navigate fertility, pregnancy, parenthood, and menopause without the fragmentation that has defined women’s health for decades. This coordinated approach led to a 7.6× increase in women’s health referrals among employer clients—showing how ecosystems, not just individual products, can expand access at scale.

Women Building the System: Female founders are increasingly acting not just as beneficiaries of funding but as architects of the system itself. Joanna Strober at Midi is reframing menopause as a mainstream health category; Kate Ryder’s Maven Clinic leads in inclusive family-building support for LGBTQ+ and single-parent families; Hillary Coles pulls menopause into the center of Hers’ consumer health brand. Emerging innovators like Elemi and Gabbi—founded by women of color—are building culturally competent tools for early cancer risk detection and maternal care in underserved communities, while companies like Wisp and Vesalius push into women’s longevity science. Much of today’s progress is coming from those closest to the problem, moving ahead even as federal research policy remains unstable.

Research Pipeline: Breakthroughs

Male Contraception (YCT-529): First human trial of hormone-free male pill completed—safe and tolerable, blocking vitamin A-derived molecule to halt sperm production. Phase 1 focused on safety; further studies testing efficacy.

Beyond One Pill: Momentum around male contraception is accelerating. Alongside YCT-529’s early safety success, other reversible methods—including a topical hormone gel and a non-hormonal injectable polymer—are progressing through clinical pipelines.

The significance is not in the molecular targets but in the broader shift: a future in which reproductive responsibility can be shared more equitably, and counseling conversations no longer rely on a binary where women carry the entire contraceptive burden.

While none of these options will reach clinical practice for several years, their advancement signals a coming expansion in family planning landscapes that will reshape how patients think about control, consent, and partnership in contraception.

Fertility Innovation (OHSU): Scientists created early-stage human eggs from adult skin cells (Nature Communications). Lab-made eggs formed embryos developing for days but with chromosomal abnormalities—no viable blastocyst yet. Proof of concept for in-vitro gametogenesis could eventually help older women, chemo survivors, same-sex couples. Dr. Mitalipov: “We know it can be done… We will figure it out.” Timeline: another decade to overcome challenges.

The Long Game: While the science remains early and imperfect, IVG’s trajectory is now unmistakable. If perfected, it could transform fertility care for older women, cancer survivors, and patients with no remaining eggs of their own.

It also raises profound questions about access—who will afford these technologies when they mature, how they’ll be regulated, and whether they’ll widen or narrow existing disparities in reproductive medicine. Birthworkers should track these developments early; innovations of this magnitude reshape counseling, ethics, and family-building landscapes long before they enter everyday practice.

Quieter Advances with Nearer Impact:

Alongside the headline-grabbing breakthroughs, the past week brought developments likely to influence care sooner:

Global guidelines updated: WHO and FIGO updated postpartum hemorrhage prevention guidelines, emphasizing earlier use of prophylactic uterotonics and tranexamic acid—especially relevant for high-risk hospitals.

Structural threats confirmed: New U.S. data linking worsening maternal health to rising infant mortality underscored that the most urgent threats remain structural: access to prenatal care, chronic disease management, and the daily stressors of poverty and racism.

Incremental innovation advancing: AI-assisted tools for earlier detection of women’s cancers, particularly endometrial cancer, are moving toward clinical pilots. Next-generation contraceptive options such as a drospirenone-only “flexible cycle” pill are entering the conversation.

These advances don’t carry the spectacle of IVG or male contraception, but they represent the incremental innovation that shapes day-to-day practice and, over time, expands women’s real reproductive autonomy.

🗺️ THE STATE-BY-STATE REALITY

Expanding Access

California: $50 million for reproductive health innovation incubators funding startups developing contraceptive technologies, telehealth platforms, maternal health diagnostics. Creates innovation ecosystem surviving regardless of federal funding.

Washington: State-funded women’s health research grants plus regulatory fast-tracks for femtech companies.

Restricting Access

Texas and Florida: Compliance barriers (registration, fees, reporting requirements) make market entry unviable for telehealth contraception and at-home diagnostics startups. Result: femtech companies not operating in these states.

For Your Practice: Patients in these states can’t access telehealth contraception platforms routine in other states. You’re practicing in policy-created innovation deserts.

Innovation Geography

73% of venture-backed femtech companies are headquartered in five states (CA, NY, MA, TX, IL). Companies pilot products where located, establish local health system partnerships, hire staff knowing local markets. If you practice in Montana, Mississippi, or West Virginia, you’re unlikely to have early access to innovations. By the time new technologies reach you, they’re established standard of care in coastal cities—widening rural-urban disparities.

🏥 WHAT THIS MEANS MONDAY MORNING

The integration of innovative femtech products into everyday practice brings immediate challenges for providers navigating workflow, financial, and equity considerations.

Provider Impact

Workflow Changes 📝

Field patient questions about innovations seen in media.

Develop criteria for evaluating femtech products.

Identify local specialists/hospitals offering new diagnostics.

Create patient education materials acknowledging insurance coverage gaps.

Administrative Burden 📋

Prior authorizations for novel diagnostics.

Training on interpreting new test results.

Determining CPT codes for services without established billing.

Informed consent for technologies with limited long-term data.

Financial Calculus 💰

Upfront costs, uncertain reimbursement, opportunity cost.

Especially challenging for practices serving low-income populations:

High-margin innovations (concierge testing for commercially insured) subsidize low-margin care (Medicaid deliveries).

If innovations only accessible to wealthy, this model collapses.

Liability Considerations ⚖️

If new diagnostic available and you don’t offer it, could you be liable if patient has bad outcome?

If new IUD has undiscovered design flaw after you’ve placed hundreds?

Where’s the line on off-label femtech use?

Patient Access Divide

Who gains: Patients in innovation hubs, commercially insured, affording $400-600 out-of-pocket, comfortable with app-based platforms.

Who’s left behind: Rural patients (limited specialist access), Medicaid patients (new technologies rarely covered until established standard of care), older adults (innovations designed for smartphone-native users), low health literacy (innovations requiring significant self-management).

Critical Equity Question: Are innovations creating additional choices or replacing essential services that used to be universally available? At-home cervical screening creates new option (additive). But if concierge maternal health practices draw OBs from safety-net hospitals, innovation widens disparities.

Risk Management

Adoption framework:

Evidence-based—what quality evidence exists?

Population-appropriate—does research include patients like yours?

Systems-ready—do you have infrastructure?

Transparent—can you explain proven versus promising?

Hype vs. Standards: TIME’s Best Inventions generates excitement, but clinical adoption requires different standards. Does it improve outcomes that matter? Is it better than current standard? Can you implement it with your patient population?

Referral Pathways

New destinations: Academic medical centers with innovation clinics, femtech direct-to-consumer platforms, research trials patients qualify for.

With federal funding threatened, connecting patients to trials is both good clinical care and advocacy—enrollment strengthens the case for continued research funding. Familiarize yourself with ClinicalTrials.gov for women’s health studies recruiting locally.

🔑 WHAT WE’RE WATCHING

This week reveals a fractured landscape where private innovation races ahead while public research infrastructure crumbles—the gap between them is an equity chasm disproportionately harming patients who most need advances.

The innovations are real: Mirvie could reduce preeclampsia mortality; Teal Wand could reach women avoiding screening; Miudella expands contraceptive options. Major VC funding ($50M to Midi, $8M to Seven Starling) shows investors recognize market opportunities in previously neglected areas.

But these follow venture capital logic: target affluent consumers first, expand later (maybe), expect profit throughout. They’re not designed to serve safety-net populations, and current policy ensures they won’t.

The Infrastructure Crisis: Every guideline you follow, every risk calculator you use, every counseling point about hormones or cardiovascular risk in pregnancy—all rest on publicly funded research current policy treats as disposable. WHI’s near-cancellation warned that politically motivated cuts can dismantle scientific foundations regardless of public health impact. The proposed NIH reorganization collapsing 27 institutes into 5 would eliminate specialized centers including the National Institute on Minority Health entirely—erasing institutional knowledge built over decades.

What Labora Collective Is Tracking

The Missing Middle: We’re watching for innovations that don’t fit the VC model—technologies serving Medicaid populations, community health centers, rural practices. These exist but struggle for funding. When philanthropy like Gates Foundation fills gaps, it’s a lifeline, not a solution. We need policy that makes safety-net innovation commercially viable, not charity-dependent.

The Gender Funding Gap Deepening: Despite femtech growing 160% faster than healthcare broadly, only 0.6% of 2025 VC went to all-female founding teams. We’re tracking whether this changes or calcifies—and whether the women building solutions for underserved populations (Elemi, Gabbi) can access capital at scale, or remain boutique operations while male-led teams capturing mixed-gender funding dominate the market.

Research-to-Practice Translation Breaking Down: The pipeline from NIH grant → clinical trial → guideline → standard of care takes 17 years in normal times. With grant freezes, researcher layoffs, and institutional chaos, that pipeline is breaking. We’re monitoring which research areas stall completely (likely: health disparities, reproductive outcomes in marginalized populations) and which accelerate via private funding (likely: profitable conditions in commercially insured populations).

State-Level Innovation Policy as Survival Strategy: California’s $50 million incubator model and Washington’s regulatory fast-tracks aren’t just nice-to-haves—they’re becoming essential as federal funding collapses. We’re watching whether other states follow this model or whether innovation concentrates further in five coastal states, creating permanent healthcare access tiers by geography.

The Coming Medicaid-Innovation Gap: Most new diagnostics and technologies take 3-5 years post-FDA approval before Medicaid covers them. With private innovation accelerating and safety-net populations disproportionately on Medicaid, we’re tracking how wide this gap becomes. Will Mirvie-like tools that could save Black maternal lives remain commercially insured privileges for a decade?

Strategic Questions for the Field

Can ethical innovation exist under venture capital incentives? We’re not convinced the answer is yes without policy intervention. VC demands returns; safety-net populations don’t generate them. Unless policy creates incentives (coverage mandates, tax credits, value-based purchasing favoring equity outcomes), the two-tier system solidifies.

Is the femtech bubble sustainable? $206 billion valuation projections assume sustained consumer willingness to pay out-of-pocket for women’s health. But $500 IUDs, $400 preeclampsia tests, $200/month menopause platforms—these work for the top 20% of earners. What happens when that market saturates and the next 80% can’t afford entry?

Who owns the data from these innovations? Digital health companies are building massive proprietary datasets on women’s bodies, fertility, pregnancies, menopause. When NIH research is public, findings benefit everyone. When private companies own the data, who benefits? We’re watching for data sharing requirements, interoperability mandates, or whether this becomes another equity barrier.

What This Means for Your Practice

You’re caught in the middle: wanting to offer best care (increasingly meaning private innovation) while aware this may widen disparities you’re trying to close. Your commercially insured patients get predictive testing; Medicaid patients get whatever coverage allows, years behind.

Adjust your approach strategically: Don’t chase every innovation, but don’t ignore genuine advances. Develop criteria: Does this address real clinical need in my population? What’s the evidence? Who accesses it? If only privileged patients can access it, can you justify implementation resources versus ensuring all patients have proven basics?

Become an advocate for public research funding: Submit comments when NIH reorganization comment period opens November 30. Respond to professional organization alerts. Offer interviews to local media on funding cuts. Your voice speaks to direct patient impact in ways researchers’ voices cannot.

Build coalitions across the divide: Partner with academic centers to get safety-net patients into trials. Develop referral relationships with community health centers. Share knowledge about which innovations work in real-world settings versus marketing hype. Connect with other practices navigating the same tensions—you’re not alone in this.

Prepare for the long game: Policy won’t improve quickly. Federal funding cuts may take a generation to reverse. You’ll practice in this fractured landscape for years, navigating between public infrastructure erosion and private innovation proliferation.

Our Commitment: Labora Collective will continue tracking the innovations that don’t make headlines—the ones designed for safety-net settings, funded by creative partnerships, and built by people closest to the problems. We’ll flag when the equity gap widens and amplify solutions that actually close it. This isn’t just about watching the future unfold; it’s about shaping it toward justice.

✨ WHAT YOU CAN DO

All Birthworkers

Immediate

Review preeclampsia screening protocols and research whether predictive diagnostics would change your practice.

Identify barriers to implementation: What does Mirvie Encompass cost in your region? Does insurance cover it? Which hospitals offer it?

Prepare patient education materials explaining new tests, out-of-pocket costs, and clinical appropriateness for different risk levels.

Advocacy

Submit comments during the November 30 NIH reorganization comment period—defend the Office of Research on Women’s Health and dedicated women’s health funding.

Use specific practice examples showing research-to-care translation (e.g., “WHI research changed how I counsel patients on hormone therapy”).

Respond to professional organization advocacy alerts from ACOG, ACNM, NAPW, or other groups already coordinating responses.

Coalition-Building

Identify one partnership across the public-private divide this quarter:

Connect patients to clinical trials at ClinicalTrials.gov

Reach out to local femtech companies or academic researchers to offer clinical perspective

Track which innovations reach which populations in your practice and share findings with professional organizations

Clinical Providers (CNMs, OBs)

Continuing Education

Develop your own framework for assessing technologies pre-adoption using the criteria in “Risk Management” section above.

Create a decision tree for your practice: What evidence is required? What implementation resources are needed? What equity concerns must be addressed before adoption?

Protocol Development

Draft protocols for innovations you’re seriously considering:

At-home screening: How do you order Teal Wand? How do you track results? What’s the workflow when HPV-positive patients need colposcopy but have avoided clinic visits?

Preeclampsia testing: How do Mirvie results change monitoring frequency, aspirin prophylaxis, delivery timing?

Reimbursement Advocacy

Document time and resources spent on prior authorizations for new technologies—quantify the administrative burden.

Share aggregated data with ACOG, ACNM, or state professional organizations to support coverage policy advocacy.

Community-Based Workers (Doulas, CHWs)

Client Education

Learn enough about key innovations (Mirvie, Teal Wand, Miudella) for informed conversations with clients.

Help clients ask the right questions of their providers: What’s my risk level? Does insurance cover this? What do I do with results? What are my options if I can’t afford it?

Resource Navigation

Compile a local innovation access map for your clients:

Which hospitals offer predictive preeclampsia diagnostics?

Which clinics have Miudella or other new contraceptive options?

What telehealth platforms operate in your state and accept Medicaid?

Equity Advocacy

Document client stories about innovation access barriers (cost, insurance, geography).

Partner with National Birth Equity Collaborative or Black Mamas Matter Alliance to ensure stories reach policymakers.

Track patterns: Are your clients systematically excluded from innovations their commercially insured counterparts receive? Share these findings with advocacy organizations.

Questions or Need Support?

Labora Collective members receive additional support for taking action on this week’s developments:

Available to Members:

Advocacy toolkits

Framework tools for evaluating femtech and developing protocols

Practice implementation guidance and reimbursement advocacy resources

Connection to member community navigating similar challenges

Deep dive continuing education on emerging innovations

Contact Labora Collective research team: LCresearch@diosara.com

About Labora Rounds

This Clinical & Medical Updates Brief is Domain 1 of the 10 weekly domain reports Labora Collective members receive, providing comprehensive intelligence across the full landscape of women’s health:

Weekly Domain Reports:

Clinical & Medical Updates (this report)

Political & Legal Developments

Economic Analysis

Health Policy Cross-Cutting

Innovation & Research Funding

Menopause & Post-Reproductive Health

Social Systems & Intimacy Crisis

Political Systems Analysis

Trump Administration Comprehensive Tracking

Immigration & Reproductive Justice

Plus:

Weekly Digest synthesizing cross-domain themes and strategic patterns

Deep Dive Reports throughout the month on critical emerging issues

Podcast Episode Summaries for quick audio insights

Not yet a member? Labora Collective equips birthworkers, clinicians, and advocates with the intelligence needed to navigate rapidly shifting policy, practice, and innovation landscapes.

Contact us at lcresearch@diosara.com.